Editorial: What Are the Remaining Challenges before Blood-Based Biomarkers for Alzheimer's Disease Can Be Used in Clinical Practice?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Validation of Plasma p-tau217 as a Biomarker of Prodromal Alzheimer's Disease.Revista de neurologia · 2026
   Article
2. Blood-based biomarkers of Alzheimer's disease: potential utility in clinical practice.Current opinion in neurology · 2026
   Review
3. Exposome influences: a multi-omics perspective on the combined toxic effects of pharmaceuticals and personal care products in Alzheimer's disease.Frontiers in toxicology · 2026
   Review
4. Disentangling relationships between Alzheimer's disease plasma biomarkers and established biomarkers in patients of tertiary memory clinics.EBioMedicine · 2025
   Article
5. P-tau217 and other blood biomarkers of dementia: variation with time of day.Translational psychiatry · 2024
   Article
6. Optimising Alzheimer's Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment.The journal of prevention of Alzheimer's disease · 2024
   Article
7. Neuroinflammation in the Evolution of Motor Function in Stroke and Trauma Patients: Treatment and Potential Biomarkers.Current issues in molecular biology · 2023
   Review
8. Opportunities to encourage adoption of a biomarker-enabled care pathway for Alzheimer's in primary care.Alzheimer's & dementia (Amsterdam, Netherlands)
   Article
9. Translating NIA-AA criteria into usual practice: Report from the ReDeMa Project.Alzheimer's & dementia (New York, N. Y.)
   Article

Corrections and comments

• Comment on
  Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force.2022

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as